Humacyte, Inc. (HUMA)
HUMA Stock Price Chart
Explore Humacyte, Inc. interactive price chart. Choose custom timeframes to analyze HUMA price movements and trends.
HUMA Company Profile
Discover essential business fundamentals and corporate details for Humacyte, Inc. (HUMA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Dec 2020
Employees
218.00
Website
https://www.humacyte.comCEO
Laura E. Niklason
Description
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
HUMA Financial Timeline
Browse a chronological timeline of Humacyte, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.10, while revenue estimate is $1.12m.
Earnings released on 13 May 2026
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $495.00k , missing expectations by -66.18%.
Earnings released on 27 Mar 2026
EPS came in at -$0.13 matching the estimated -$0.13, while revenue for the quarter reached $467.00k , missing expectations by -65.39%.
Earnings released on 12 Nov 2025
EPS came in at -$0.14 surpassing the estimated -$0.17 by +17.65%, while revenue for the quarter reached $753.00k , missing expectations by -44.18%.
Earnings released on 11 Aug 2025
EPS came in at -$0.24 falling short of the estimated -$0.15 by -60.00%, while revenue for the quarter reached $301.00k , missing expectations by -67.21%.
Earnings released on 13 May 2025
EPS came in at -$0.10 surpassing the estimated -$0.19 by +47.37%, while revenue for the quarter reached $517.00k , missing expectations by -32.40%.
Earnings released on 28 Mar 2025
EPS came in at -$0.16 surpassing the estimated -$0.23 by +30.43%, while revenue for the quarter reached $7.23m , beating expectations by +1.03k%.
Earnings released on 8 Nov 2024
EPS came in at -$0.33 falling short of the estimated -$0.26 by -26.92%.
Earnings released on 13 Aug 2024
EPS came in at -$0.27 falling short of the estimated -$0.23 by -17.39%.
Earnings released on 10 May 2024
EPS came in at -$0.29 falling short of the estimated -$0.23 by -26.09%.
Earnings released on 22 Mar 2024
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $10.79m , beating expectations by +17.88k%.
Earnings released on 9 Nov 2023
EPS came in at -$0.25 matching the estimated -$0.25.
Earnings released on 14 Aug 2023
EPS came in at -$0.22 matching the estimated -$0.22.
Earnings released on 12 May 2023
EPS came in at -$0.22 matching the estimated -$0.22.
Earnings released on 24 Mar 2023
EPS came in at -$0.21 surpassing the estimated -$0.24 by +12.50%, while revenue for the quarter reached $5.00k , missing expectations by -97.50%.
Earnings released on 10 Nov 2022
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%, while revenue for the quarter reached $31.00k , missing expectations by -84.77%.
Earnings released on 12 Aug 2022
EPS came in at -$0.19 surpassing the estimated -$0.22 by +13.64%, while revenue for the quarter reached $1.30m , beating expectations by +452.68%.
Earnings released on 13 May 2022
EPS came in at -$0.22 falling short of the estimated -$0.21 by -4.76%, while revenue for the quarter reached $233.00k , missing expectations by -1.02%.
Earnings released on 29 Mar 2022
EPS came in at -$0.22 falling short of the estimated -$0.19 by -15.79%, while revenue for the quarter reached $177.00k , missing expectations by -27.95%.
Earnings released on 12 Nov 2021
EPS came in at -$0.72 falling short of the estimated -$0.21 by -242.86%, while revenue for the quarter reached $241.00k .
Earnings released on 16 Aug 2021
EPS came in at -$0.17 surpassing the estimated -$0.56 by +70.18%, while revenue for the quarter reached $690.00k .
HUMA Stock Performance
Access detailed HUMA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
